According to related industries, both Roche's Rozlytrek (NTRK) anticancer drugs, Roche Korea's Rozlytrek and Bayer Korea's Vitrakvi, failed to conclude discussions with the NHIS (60 days) in January.

The two drugs seeking the PE system passed the HIRA's Drug Benefit Evaluation Committee last year, but are in the final stage. If the extended negotiations are concluded as soon as possible, both drugs can be applied in March, but as they are the first drugs to be applied to multiple solid cancers only for certain genetic mutations, it remains to be seen whether the government and pharmaceutical companies can reach an agreement.

Among adult and pediatric patients with NTRK gene fusion without